Skip to main content

Table 1 Baseline characteristics by treatment (%)

From: Safety and efficacy of lumefantrine-artemether (Coartem®) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults

  SP
N = 486
AL
N = 485
Mean weight (Kg) (SD) 56.4 (10.1) 56.3 (9.6)
Number of women (%) 245 (50.5) 230 (47.4)
Mean age (yr) (SD) 27.0 (8.9) 26.3 (8.3)
Mean body temperature (°C) (SD) 37.2 (1.2) 37.3 (1.3)
Mean white blood cell count (n*109/l) (SD)* 5.1 (1.8) 5.2 (1.8)
Mean Hb (g/l) (SD) 13.0 (2.2) 13.2 (2.3)
Mean (geometric) parasite density(/μl) (range)* 8787 (406 – 103680) 8405 (350–158894)
Gametocytes prevalence (n)(%) 16 (3.3) 18 (3.7)
  N = 477 N = 481
Weakness (%) 344 (72.1) 365 (75.9)
Headache (%) 428 (89.7) 429 (89.2)
Muscle/joint pain (%) 316 (66.2) 318 (66.2)
Dizziness (%) 176 (36.9) 177 (36.7)
Nausea (%) 190 (39.9) 180 (37.5)
Vomiting (%) 104 (21.7) 113 (23.5)
Diarrhoea (%) 62 (13.1) 59 (12.2)
Abdominal pain (%) 172 (36.1) 163 (33.8)
Heart palpitations (%) 76 (16.0) 76 (15.7)
Backache (%) 105 (22.0) 119 (24.7)
Jaundice** (%) 51 (10.7) 104 (21.7)
Pallor** (%) 6 (1.3) 1 (0.3)
Dark urine (%) 51 (10.6) 48 (9.9)
  1. *Data on WBC were missing in 4 patients in the SP group and in 7 in the AL group. Parasite density was calculated based on the parasites/WBC ratio.
  2. ** Jaundice and pallor in 302 patients in the SP and and 301 in the AL group.
\